CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/38819

Title:	CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC
Authors:	GROHE, C.; JOHNSON, B. E.; KIM, T. M.; HILTERMANN, T. J. N.; BARLESI, F.; GOTO, Y.; GUNNARSSON, O.; OVERBECK, T.; REGUART, N.; WERMKE, M.; CASTRO JR., G. de; FELIP, E.; GREYSTOKE, A.; SOLOMON, B. J.; DEUDON, S.; LOUVEAU, A. -L.; PASSOS, V.; TAN, D. S. W.
Citation:	ONCOLOGY RESEARCH AND TREATMENT, v.43, n.SUPPL 4, suppl.4, p.152-152, 2020
Appears in Collections:	Comunicações em Eventos - FM/MDR Departamento de Radiologia - FM/MDR Comunicações em Eventos - HC/ICESP Instituto do Câncer do Estado de São Paulo - HC/ICESP Comunicações em Eventos - LIM/24 LIM/24 - Laboratório de Oncologia Experimental

Files in This Item:

There are no files associated with this item.